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Data  from  a  variety  of systems  indicate  that  several  distinct  populations  of T 
lymphocytes are involved in the process of immune suppression (1-3). These suppres- 
sor T  cells (Ts) 1 function in a defined sequence. The nature of these cells and the Ts- 
derived factors (TsF) involved in the suppressor pathway have not been fully resolved, 
but  in  at  least  two  independent  systems three  separate  Ts  populations  have been 
identified  (4-6). These Ts populations have been termed Tsl, Ts2, and Ts3.  Many of 
the  Ts  described  in  the  literature  have  properties  similar  to  one  of  these  three 
populations.  Although  it  is  difficult  to  classify  all  Ts  reported  in  this  simplified 
suppressor  cell  cascade,  many of the  discrepancies  might  reflect  differences  in  the 
various  assay conditions  used  rather  than  implying the  existence of several totally 
distinct suppressor cell pathways. 
One of the most frequently defined Ts cell types appears to correspond to the Tsa 
population identified in the 4-hydroxy-3-nitrophenyl acetyl (NP)  suppressor system. 
This suppressor cell population is derived from antigen-primed mice, may represent 
the final or effector cell in the Ts pathway, has the Lyt  1-, Lyt 2 +, I-J  + phenotype, 
and produces a soluble TsF that may under selected conditions be nonspecific (4,  7). 
Ts cells that fit most of these criteria have also been identified in the azobenezenear- 
sonate (6, 8), dinitrophenyl  (9), trinitrophenyl (10), keyhole limpet hemocyanin (11), 
and sheep erythrocyte (12)  systems. 
This report focuses on the mechanism of Tsa cell activation and the specificity of 
Tsa cells, especially those obtained from F1  hybrid mice. The NP suppressor system 
was chosen to study these parameters because the methods for assaying Ts3 activity 
independent  of Tsl  or  Ts2  activity  had  been  established  (4,  5).  Furthermore,  we 
previously  characterized  (13)  suppressor  factors  (TsF2)  derived  from  a  series  of 
monoclonal Tsz hybridomas that could be used to activate Tsa cells. The present data 
demonstrate that the suppressive activity of the Ts3 population is not manifest unless 
these  cells  are  specifically activated  by  TsF2.  Furthermore,  the  data  suggest  that 
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Program, Division of Research Resources, National Institutes of Health, and by grant CA-14723 from the 
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distinct  clones  of  Fl-derived  suppressor  cells  are  restricted  to  each  parental  H-2 
haplotype. Thus, Ts cells, like helper T  cells, appear to be restricted in their ability to 
recognize antigen in the context of major histocompatibility complex gene products, 
but  in  the  Ts  pathway,  antigen  may  be  associated  with  I-J  products  instead  of 
products of the I-A or I-E loci. 
Materials and Methods 
Mice.  All mice were either purchased from The Jackson Laboratory, Bar Harbor, ME, or 
were bred in the animal facilities  at Harvard Medical School,  Boston, MA. Mice were used at 
3-12 mo of age and were maintained on laboratory chow and acidified, chlorinated water ad 
lib. 
Animals used  in  this  study  were  maintained in  accordance with  the  guidelines of the 
Committee on Animals of the Harvard Medical School and those prepared by the Committee 
on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, 
National Research Councel (DHEW publication (NIH) 78-23, revised 1978). 
Antigens.  NP-O-Succinimide (NP-O-Su) was purchased from Biosearch Co., San Rafael, 
CA. Dimethylsulfoxide (DMSO) was purchased from Fisher Scientific Co., Pittsburgh, PA. 2,4- 
dinitro-1-fluorobenzene  (DNFB) was obtained from Eastman Kodak Co., Rochester, NY. 
Antisera.  Both B10.A(3R) anti-B10.A(5R) (anti-I-J  k) and B10.A(5R) anti-B10.A(3R) (anti- 
I-J  b) were produced by immunization  with spleen and lymph node cells as described elsewhere 
(14). 
Treatment of Lymph  Node Cells with Anti-I-J Antisera and Complement.  7.5 ×  107 NP-immune 
lymph node cells were pelleted and incubated in 1.0 ml of a  1:5 dilution of B10.A(3R) anti- 
B 10.A(5R)  (anti-I-J  k) or B 10.A(SR) anti-B  10.A(3R)  (anti-I-J  b) antisera. After 30 rain at room 
temperature, cells were spun and resuspended in 1.0 ml of rabbit complement diluted 1:5 or 
1:8 in Hanks' balanced salt solution. After an additional 30-min incubation at 37°C, the cells 
were washed three times and then activated with TsF2, as detailed below. 
In  Vitro Activation of NP-primed  Lymph Node Tsa Cells with  TsF2.  Regional lymph node ceils 
from mice that had been immunized subcutaneously with 2 mg NP-O-Su were used as  the 
source of Ts3 cells. B6-Tsz-28 and CKB-Ts2-59-derived TsF2, which have been characterized 
and described (13), were used for activation of lymph node Tss cells  in vitro. 5 ×  107 NP- 
primed lymph node cells were cultured for 2 or 48 h in 10 ml RPMI 1640 with 10% fetal calf 
serum and 0.1 mM Hepes plus 50/~1 TsFz ascites fluid derived from B6-Tsz-28, CKB-Ts2-59,  or 
BW5147 cells that were grown in (AKR × B6)F1, (AKR × CKB)F1, or AKR mice, respectively. 
After culture, these activated lymph node cells were washed three times with Hanks' balanced 
salt solution and resuspended. 
Functional Analysis  of the Activated NP-primed  Lymph  Node Ts3 Cells m  Cyclophosphamide-treated 
Antigen-primed Mice.  Mice were primed subcutaneously with 2 mg of NP-O-Su in DMSO on 
day 0, as described elsewhere  (15). 24 h later, they were treated with an intraperitoneal  injection 
of 20 m~/kg cyclophosphamide (CY)  in saline. On day 6, each mouse received intravenously 
1 ×  10  NP-primed lymph node cells  activated with  TsF2  or  control BW5147  factors,  as 
described above, or received 0.5  ml of TsF2  or control BW5147  factors.  Immediately after 
transfer, mice were challenged in the left  footpad with 0.025  ml PBS solution containing 30 
#g of NP-O-Su (prepared by mixing 25/d of a 2% NP-O-Su/DMSO solution in 0.4 ml PBS). 
Footpad swelling was measured 24 h later. Swelling was determined as the difference, in units 
of 10  -3 cm, between the left  and right footpad  thicknesS.' It should be noted that  1 ×  107 
immune lymph node cells  are not sufficient to transfer immunity under these experimental 
conditions. 
DNFB Contact Sensitivity Responses.  Contact sensitivity was induced by two daily paintings 
on the shaved abdomen with 25/~1 of 0.5% DNFB solution in acetone: olive oil (4:1) (16). 5 d 
after the last painting, 20/d of 0.2% DNFB in the same vehicle was applied to the left ear, and 
the ear swelling was measured as the difference between the left and right ear thicknesses. 
Double Antigen Ear Challenge.  Individual mice were immunized with either DNFB alone or 
DNFB +  NP-O-Su, as described above. Mice were challenged in the left ear by painting with 
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0.7% NP-O-Su in DMSO with 0.4 ml PBS, pH 7.7), or with both antigens.  The incremental 
ear swelling was measured 24 h thereafter. The concentration and volume of NP-O-Su used to 
challenge was predetermined  to elicit  high  specific  ear swelling  and  low  nonspeeifie  back- 
grounds. 
Percent Suppression.  The percent suppression  in  the  present  study was  calculated  by the 
following formula: percent suppression =  100 x  [(swelling of group receiving Tss cells activated 
with  BW5147  tumor ascites  -  swelling  of group receiving Ts3 cells activated with  TsF2)/ 
(swelling  of group  receiving Tss cells  activated with  BW5147  tumor ascites  -  swelling  of 
unprimed group)]. 
Data Analysis.  Statistical  analysis of the experimental data with  respect to controls was 
calculated using the two-tailed Student's t test. 
Results 
In Vitro Activation of Tsa Cells.  To demonstrate that Ts2-derived factor could activate 
Tss cells, we took advantage of past observations on the biological properties of the 
Ts3  cell  population.  Thus,  it  was  previously  shown  that  the  Ts3  population  was 
sensitive to  (CY)  treatment  and,  furthermore,  that  lymph node cells from antigen- 
primed mice could be used in adoptive transfer experiments to restore Tss activity to 
the CY-treated recipients (4).  To directly activate Tsz cells, we incubated 0.05 ml of 
BW5147  control  or Ts2  hybridoma-derived  ascites with  5  ×  10  7  NP-O-Su-primed 
lymph node cells in 10 ml of RPMI 1640 media containing 10% fetal calf serum. The 
cells were cultured for 48 h at 37 ° in  10% CO2. After 48 h of in vitro culture, the cells 
were washed extensively, and  1 X  107 viable lymph node cells were injected intrave- 
nously into syngeneic recipients that had been previously primed with NP-O-Su and 
treated 24 h  later with 20 mg/kg CY. In confirmation of previous findings  (5), CY- 
treated recipients were not sensitive to suppression by monoclonal B6-Ts2-28 or CKB- 
Ts2-59 suppressor factor (Table I). However, significant suppression of the cutaneous 
sensitivity (CS) response was observed when CY-treated recipients were given lymph 
node cells derived from NP-O-Su-primed C57BL/6 mice that were activated in vitro 
with B6-Ts2-28-derived TsF2. As specificity controls, factors from the BW5147 tumor 
line or from the CKB-Ts2-59 line failed to activate suppressive activity in these cells. 
The failure of CKB-Ts2-59-derived TsF2 to activate C57BL/6 antigen-primed lymph 
node cells is presumably due to the H-2-1inked (I-J) genetic restriction of TsF2  (13). 
Thus,  the  B6-Ts2-28 factor that  is derived  from C57BL/6  (H-2  b, Igh  b)  cells is only 
active in recipients that are matched at the I-J and Igh regions (13). The CKB-Ts2-59 
factor is of CKB  (H-2  k, Igh  b) origin and is also genetically restricted by I-J and Igh 
genes. To verify that the CKB-Ts2-59 factor was capable of activating antigen-primed 
lymph node cells of the appropriate strain, a reciprocal experiment was performed. As 
shown  in  Table  I,  the  CKB-Ts~-59 factor activated Tsz suppressive activity when 
incubated  with  H-2  and  Igh-matched  B10.BR  lymph  node  cells,  whereas  the 
C57BL/6-derived Ts2 factor failed to induce suppression under the same experimental 
conditions. 
Kinetics of Tss Activation.  Lymph node cells from C57BL/6 mice were cultured with 
B6-Ts2-28 or control BW5147-derived factors for various intervals ranging from 5 rain 
to 48 h. The cells were then washed and assayed for suppressive activity in NP-O-Su- 
primed CY-treated  C57BL/6  recipients.  As shown  in  Fig.  1,  maximum suppressive 
activity was noted after 1-2 h of in vitro activation with TsF2. Activation of Tss cells 
with TsF2 for up to 48 h  did not result in an increased level of immune suppression. 
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TABLE  I 
In  Vitro Activation  of Suppressor Cells with  TsF~  * 
Donor of NP-  NP-primed,  Footpad swelling 
TsFz source  primed lymph  CY-treated 
node cells  recipients  ±  SE (10 -3 cm) 
BW5147  None  C57BL/6  38.8:1:1.4 
B6-Ts2-28  None  C57BL/6  38.0 ±  2.0 
BW5147  C57BL/6  C57BL/6  37.5 ±  1.0 
B6-Ts2-28  C57BL/6  C57BL/6  15.8 +  1.8:1: 
CKB-Ts2-59  C57BL/6  C57BL/6  35.0 +  3.8 
BW5147  None  BI0.BR  27.0 ±  1.8 
CKB-Ts~-59  None  B10.BR  28.0 +  2.6 
BW5147  B10.BR  B10.BR  26.3 zt:  1.3 
CKB-Ts2-59  B10.BR  B10.BR  14.3 ±  1.2:~ 
B6-Ts2-28  BI0.BR  B10.BR  27.3 +  1.7 
* Regional lymph node cells  from mice that had been immunized subcutane- 
ously with  2  mg NP-O-Su  were cultured  for  48  h  with  TsF~  or  control 
BW5147  ascites for activation,  then washed and  transferred to designated 
recipients. Groups of recipient mice were immunized with 2 mg NP-O-Su. 
24 h later, they were treated with intraperitoneal injections of 20 mg/kg CY. 
On day 6, each mouse received  1 x  10  7 activated  NP-primed lymph node 
Tsa,  and  the  recipients were challenged  after cell  transfer. The data  were 
expressed as the increment of footpad swelling :1: SE in units of 10  -s cm. The 
background response of nonimmunized C57BL/6 mice was 12.5 +  1.3 and 
that of B10.BR was 7.3 +  1.1. 
~: Significant suppression, P <  0.001. 
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FIG.  1,  Kinetics of in vitro activation of lymph node cells  from NP-O-Su-primed mice with TsF2. 
C57BL/6  mice were immunized with 2 mg NP-O-Su. After 6  d, the regional lymph nodes were 
removed, teased, and the cells were cultured for 5 min to 48 h with TsF2 or control BW5147 ascites 
for activation. The Tsa cells were then washed and used for transfer. Groups of recipient mice were 
immunized with 2  mg NP-O-Su.  24  b  later,  the  recipients were treated  with an  intraperitoneal 
injection of 20 mg/kg CY. On day 6, each mouse received 1 X 107 activated NP-primed lymph node 
Tss cells intravenously. The mice were then challenged. The data represent pooled results from two 
separate experiments. The data were normalized and the percent suppression +  SE was calculated. 
O, TsF2; C), BW. MUTSUHIKO MINAMI, SHUICHI FURUSAWA, AND MARTIN  E.  DORF  469 
was evaluated in two ways. First, NP-O-Su or DNFB antigen-primed  C57BL/6 lymph 
node cells were used as the source of Tsa cells for activation with TsFz. Second, these 
activated cells were tested for suppressive activity in syngeneic C57BL/6 recipients 
primed with either DNFB or DNFB +  NP-O-Su. In these experiments the mice were 
challenged by injection of NP-O-Su into the left ear pinna or by painting the left ear 
with DNFB or both. The control right ear was untreated. As shown in Table II, the 
only condition in which  significant levels of suppression were  observed was  when 
hybridoma-derived TsF2 was used to activate Tss cells from NP-O-Su-primed mice 
and when these activated Tsa cells were tested in animals primed and challenged with 
NP-O-Su. The suppression was not due to the carry over of B6-Ts2-28 factor because 
intravenous injection of TsF2 did not suppress CY-treated recipients (Table II). NP- 
specific TsF2 would not activate lymph node cells from  DNFB-primed mice, even 
when these cells were tested in DNFB-primed and challenged recipients. Furthermore, 
there is no apparent suppression of a  bystander DNFB response when activated Tss 
cells are transferred to recipients that had been either doubly primed or challenged 
with DNFB +  NP-O-Su (Table II). 
Genetic  Restrictions  on  Ts3  Cell  Activation  and  Function.  One  of the  advantages  of 
activating Tsa cells  in  vitro  is  that  it  permits  independent analysis of the  genetic 
restrictions  for  Tsa  activation  and  Tsn-target  cell  interactions.  Control  BW5147, 
C57BL/6  (H-2  b,  Ighb),  and  CKB  (H-2  k,  Ighb)-derived TsF2  were  incubated with 
C57BL/6, B10.BR  (H-2  k, Ighb), CKB, or C3H  (H-2  k, Igh  ~)  NP-O-Su-primed lymph 
node cells. Tss activation was assessed by adoptively transferring the in vitro activated 
TABLE II 
Specificity of m  Vitro Ts~ Cell Activation* 
48-h Tss activation  Antigen for ear challenge 
Priming of CY- 
Antigen for  treated recipient  NP-O-Su  DNFB 
TsF2 source  Tss priming 
NP-O-Su + 
DNFB 
BW5147 (i.v.)  --  NP + DNFB  16.3 ± 0.3  10.8 :lz 0.3 
B6-Ts2-28 (i.v.)  --  NP + DNFB  17.3 :t 0.5  NT$ 
BW5147  NP-O-Su  NP + DNFB  16.5 ± 0.6  10.5 + 0.3 
B6-Ts2-28  NP-O-Su  NP + DNFB  8.3 ±  1.0§  10.3 ± 0.5 
BW5147  DNFB  NP + DNFB  14.3 ± 3.4  10.0 ±  1.1 
B6-Ts2-28  DNFB  NP + DNFB  18.0 ± 0.4  11.8 ±  1.8 
BW5147  --  None  4.0 ± 0.4  1.0 ± 0.6 
BW5147 (i.v.)  --  DNFB  18.0 + 0.8 
B6-Ts2-28 (i.v.)  --  DNFB  18.8 ± 0.5 
BW5147  NP-O-Su  DNFB  17.3 ± 0.5 
BW5147  DNFB  DNFB  16.8 + 0.5 
B6-Ts2-28  NP-O-Su  DNFB  18.8:1:1.2 
B6-Ts~-28  DNFB  DNFB  17.0 ±  1.2 
BW5147  --  None  5.0 ± 0.6 
* Regional lymph node cells from mice that had been immunized with DNFB or NP-O-Su were cultured 
with B6-Ts2-28 or control BW5147 ascites for activation. Groups of recipient mice were primed with 
DNFB alone or DNFB and NP-O-Su. 24 h later, all groups were given 20 mg/kg CY. 6 d later, mice were 
given the in vitro activated Tsa cells and challenged with DNFB or NP-O-Su alone or with DNFB and 
NP-O-Su. 
$ Not tested. 
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Tsa cells to antigen-primed  CY-treated  C57BL/6,  B10.BR,  CKB,  or C3H  recipients. 
Activated  Tss cells were transferred during  the effector phase of the CS response, i.e., 
on  the  day  of antigen  challenge.  Such  effector  phase  transfers  minimize  potential 
allogeneic effects because the Tsn cells are only present in the allogeneic environment 
for  24  h  before  termination  of the  assay.  Furthermore,  the  BW5147-activated  Ts3 
lymph  node  population  serves  as  a  control  for  nonspecific  suppression.  The  data 
shown  in  Table  III  were  derived  from  seven  independent  experiments  that  were 
normalized  and  pooled.  Activation  of the Ts3 population  was generally assayed after 
2  h  of  incubation  with  TsF2.  After  activation  of  the  Tsz-containing  lymph  node 
population,  suppressive  activity  was  only  noted  in  combinations  of TsF2,  Ts3,  and 
recipients that were matched  at the H-2 and  Igh gene complexes.  Thus, after a  2  h  in 
vitro  activation,  C57BL/6  (H-2b)-derived TsF~  activated  C57BL/6  but  not  B10.BR 
TAaLE  III 
Genetic Restrictions  on  Tsa Cell Activation  and FunctionS* 
TsF2 source  Tsa donor  CY-treated  Normalized percent 
recipients  suppression ±  SE 
BW5147  C57BL/6  C57BL/6  0 ±  3  (7) 
B6-Ts2-28  C57BL/6  C57BL/6  51 ± 5  (8):[: 
CKB-Ts2-59  C57BL/6  C57BL/6  5 ±  7  (4) 
BW5147  BI0.BR  C57BL/6  0 ± 4  (4) 
B6-Ts2-28  B10.BR  C57BL/6  -5 ± 4  (4) 
CKB-Ts2-59  BI0.BR  C57BL/6  2 ± 6  (4) 
BW5147  C57BL/6  BI0.BR  0 +  3  (4) 
B6-Ts2-28  C57BL/6  BI0.BR  7 ± 8  (4) 
CKB-Tsz-59  C57BL/6  BI0.BR  6 ±  19  (4) 
BW5147  B10.BR  B10.BR  0 ±  7  (4) 
B6-Ts~-28  BI0.BR  BI0.BR  3 ± 9  (4) 
CKB-Tsz-59  BI0.BR  B10.BR  55 ±  10  (4):1: 
BW5147  CKB  B10.BR  0 ± 9  (4) 
B6-Ts2-28  CKB  BI0.BR  -I  +  I 1  (4) 
CKB-Ts2-59  CKB  BI0.BR  80 ± 8  (4):[: 
BW5147  C3H  B10.BR  0 ± 6  (8) 
B6-Ts2-28  C3H  B10.BR  -4 +  7  (7) 
CKB-Ts2-59  C3H  B10.BR  2 ±  7  (8) 
BW5147  CKB  CKB  0 ± 6  (9) 
CKB-Ts~-59  CKB  CKB  59 ± 4  (9)$ 
BW5147  CKB  C3H  0 ±  7  (8) 
CKB-Ts2-59  CKB  C3H  3 ±  5  (8) 
BW5147  None  C57BL/6  0 ±  7  (5) 
B6-Ts2-28  None  C57BL/6  -3 ±  5  (4) 
BW5147  None  B10.BR  0 ± 8  (5) 
CKB-Ts2-59  None  B10.BR  -3 ±  19  (4) 
* In vitro activation of regional lymph node Tsz cells from NP-O-Su-primed 
mice with TsF2 was done as described in Materials and Methods. Activation 
was continued for 2 h except for one experiment in which a 48-h activation 
was used.  Recipient mice were primed with NP-O-Su;  24 h  later all mice 
were  given 20 mg/kg cyclophosphamide, and 6  d  later received  1 ×  107 
activated Ts3 before antigen challenge. The data represent the pooled results 
from  seven  separate  experiments  (not  all  groups  were  included  in  each 
experiment). The data were normalized and the percent suppression +  SE 
was calculated. The number of mice is indicated in parentheses. 
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(H-2  k)  Tsa  cells  that  only  functioned  when  adoptively  transferred  to  syngeneic 
C57BL/6 recipients. Similarly, after 2 h  of activation with CKB  (H-2k)-derived TsFs, 
only B10.BR or CKB Ts3-containing lymph node cells were activated. Furthermore, 
the activated B10.BR  or CKB  Tss population would suppress CS responses in  H-2 
and  Igh-matched  B10.BR  and  CKB  recipients but  not  in  Igh-disparate C3H  mice 
(Table III). To prove that the suppression was mediated by activated Tsa cells instead 
of TsF2 that might have been passively transferred along with the Tss cells, we injected 
TsF~ intravenously into NP-O-Su-primed (3Y-treated recipients. As shown  in Table 
III,  administration  of  TsF2  without  added  Tss  cells  was  unable  to  suppress  CS 
responses in antigen-primed (3Y-treated recipients. 
I-J Restriction of Activated Ts~  Because after a  2-h activation period the TsFa-Tsa- 
target cell interactions are H-2 restricted, we next asked which subregion within the 
H-2  complex was  responsible for this  genetic restriction.  Based on several previous 
studies that indicated that suppressor cell restrictions were generally mediated through 
the  I-J subregion  (5,  13,  17), we  tested  two  congenic strains  of mice,  3R(I-J  b)  and 
5R(I-Jk), that only differ with respect to their I-J subregions. The data in Table IV 
demonstrate that using 2-h activation conditions, suppression is only observed when 
the TsFs-Ts3 and the recipient strain are matched at the I-J subregion. The controls 
for  these  experiments  were  similar to  those  used  in  the  previous  experiments  and 
demonstrate that the results are not due to carry over of TsF2 (Table IV). 
Activation and Function of Ts3  Cells Derived from  F1  Mice.  To  further  analyze  the 
TABLE  IV 
I-J Restrictions of In Vitro Activated Tsa Cells* 
NP- 
TsF~ source  Tss donor  primed,  Normalized percent 
CY-treated  suppression ± SE 
recipients 
BW5147  5R  5R  0 + 6  (8) 
B6-Tsz-28  5R  5R  7 ± 5  (7) 
CKB-Tss-59  5R  5R  50 ± 6  (8)$ 
BW5147  3R  5R  0 "4- 4  (8) 
B6-Tss-28  3R  5R  3 "4- 5  (8) 
CKB-Tss-59  3R  5R  15 -t- 3  (8) 
BW5147  None  5R  0 ± 4  (8) 
CKB-Tss-59  None  5R  8 ±  13  (8) 
BW5147  5R  3R  0 + 5  (8) 
B6-Tss-28  5R  3R  6 ± 7  (7) 
CKB-Tss-59  5R  3R  -1 ±  10  (8) 
BW5147  3R  3R  0 ±  11  (8) 
B6-Tsz-28  3R  3R  59 + 8  (8)$ 
CKB-Tss-59  3R  3R  -ll  ±  11  (8) 
BW5147  None  3R  0 ± 6  (10) 
B6-Tss-28  None  3R  7 ± 5  (8) 
* Refer to legend for Table III for protocol. Regional lymph node cells from 
NP-primed mice were cultured with TsFz for 2 h. The data represent the 
pooled results from three separate experiments. The data were normalized 
and the percent suppression :1: SE was calculated. 
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restrictions  on Ts3 cell  interactions  and  to evaluate whether allogeneic effects could 
influence the results,  we activated  NP-O-Su-primed  (B10 ×  B10.BR)F1 lymph node 
cells  with  C57BL/6,  CKB, or control  BW5147-derived TsF2 for 2  h  in vitro.  These 
activated  Fa cells were transferred  to NP-O-Su-primed CY-treated  C57BL/6  (H-2  b) 
or  B10.BR  (H-2  k)  recipients.  The  data  in  Table  V  again  clearly  demonstrate  an 
absolute requirement  for H-2 homology between the TsF2 and the recipient strain to 
obtain  immune  suppression.  Thus,  C57BL/6  (H-2b)-derived  TsF2 activates  (B10  × 
B10.BR)Fa Ts3 cells, but these cells only function in C57BL/6 (H-2  b) not B10.BR (H- 
2 k)  mice.  In  a  reciprocal  experiment,  CKB  (H-2k)-derived  TsF2  activated  (B10  × 
B 10.BR) F1 Ts3 cells, but again these F1 cells only produce suppression when transferred 
into H-2k-bearing B10.BR recipients. 
The simplest  hypothesis that would account for the above observation is that two 
distinct  Tsa  populations  exist  in  lymph  node  cells  derived  from  F1  animals;  one 
population  is  restricted  by I-J  b gene products  and  the  other  by I-J  k gene products. 
This hypothesis parallels  the situation  observed with helper T  cells derived  from F1 
mice in  which  two  functionally  distinct  populations  exist  and  each  is  restricted  by 
different I region genes (18,  19).  Another possibility to account for these observations 
is that the I-J gene products are allelically expressed on the F1 cells. To test the latter 
possibility,  B10.BR,  C57BL/6, or (B10  ×  B10.BR)Fa  NP-O-Su-primed lymph node 
cells were treated with anti-I-J  k or anti-I-J  b alloantisera  plus complement before a  2- 
h  activation with TsF2.  As shown  in Table VI, treatment  of B10.BR Ts3 cells  with 
anti-I-J  k specifically depleted the ability to generate suppressive activity. In reciprocal 
groups,  treatment  of C57BL/6 Ts3 cells with anti-I-J  b but  not  anti-I-J  k alloantisera 
completely eliminated Ts3 cell activity. When the same anti-I-J alloantisera were used 
to lyse (B 10 ×  B 10.BR)Fa Ts3 cells, both anti-I-J  b and anti-I-J  k alloantisera eliminated 
the  ability  to  generate  functional  Ts3 cells.  Thus,  it  appears  that  Ts3 cells  derived 
from (B 10 ×  B 10.BR)F1 donors carry both the I-J  k and I-J  b antigenic determinants in 
a  codominant fashion. 
Suppression of H-2 Heterozygous F1 Recipients by Activated Tsa Cells.  Finally, to evaluate 
TABLE V 
Activation of Ts3 Cells  from F1 Hybrid Mice  * 
TsF2 source  Tsa donor 
Normalized 
CY-treated  percent  CS 
recipients  suppression 
+ SE 
* Refer to legend for Table III for protocol. The 2 h-activation data represent 
the pooled results from two separate experiments. The data were normalized 
and the percent suppression + SE was calculated. 
Significant suppression, P < 0.01. 
BW5147  (B10 x  B10.BR)F1  C57BL/6  0 + 4  (8) 
B6-Tse-28  (B10 x B10.BR)Fx  C57BL/6  43 + 3 (8)z~ 
CKB-Ts~-59  (B10 x B10.BR)Ft  C57BL/6  I __. 5 (8) 
BW5147  (BI0 x B10.BR)F~  BI0.BR  0 + 6  (8) 
B6-Ts2-28  (B10 x BI0.BR)Fa  B10.BR  -2 + 6  (8) 
CKB-Ts2-59  (B10 x Bl0.BR)F1  B10.BR  54 +- 6  (7)~ 
BW5147  None  C57BL/6  0 + 5  (10) 
B6-Ts2-28  None  C57BL/6  -2 :t: 3 (8) 
BW5147  None  B10.BR  0 -4- 6  (10) 
CKB-Ts2-59  None  BI0.BR  -4 + 9  (8) MUTSUHIKO MINAMI, SHUICHI FURUSAWA, AND MARTIN E.  DORF 
TABLE  VI 
Ft-derived Tsz Cells Bear Both Parental IJ Determinants * 
473 
NP-primed  Normalized percent 
TsF2 source  Tsa donor  Ts3 treatment  CY-treated  CS suppression 
recipient  ±  SE 
BW5147  B10.BR 
B6-Ts2-28  B 10.BR 
CKB-Ts2-59  B 10.BR 
CKB-Ts2-59  B 10.BR 
CKB-Ts2-59  B 10.BR 
BW5147  C57BL/6 
B6-Ts~-28  C57BL/6 
B6-Ts2-28  C57BL/6 
B6-Ts2-28  C57BL/6 
BW5147  (B10 × B10.BR)F~ 
B6-Ts2-28  (B10 × BI0.BR)F~ 
CKB-Ts2-59  (BI0 × B10.BR)F1 
CKB-Ts2-59  (B10 × BI0.BR)F1 
CKB-Ts2-59  (B10 × B10.BR)F1 
BW5147  (BI0 X B10.BR)F~ 
CKB-Ts2-59  (B10 × B10.BR)F1 
B6-Ts2-28  (BI0 × B10.BR)F1 
B6-Ts2-28  (B10 ×  BI0.BR)F~ 
B6-Tsa-28  (B10 X B10.BR)F1 
--  B10.BR  0  ±  4  (12) 
--  BI0.BR  -1  ±  1l (4) 
--  B10.BR  78  ±  4  (12):~ 
Anti-IJ  k + C  B10.BR  7 ±  8  (12) 
Anti-IJ  b + C  B10.BR  80  ±  6  (8):~ 
--  C57BL/6  0  +  4  (8) 
--  C57BL/6  64  +  5  (6):~ 
Anti-IJ  k + C  C57BL/6  43  -4- 9  (7):~ 
Anti-IJ  b + C  C57BL/6  -1  ±  4  (8) 
--  B10.BR  0  ±  3  (12) 
--  BI0.BR  2  +  5  (12) 
--  B10.BR  61  ±  5  (11):~ 
Anti-IJ  k + C  BI0.BR  3  ±  6  (12) 
Anti-IJb+C  B10.BR  11  +  7  (8) 
--  C57BL/6  0  ±  3  (12) 
--  C57BL/6  4  ±  4  (12) 
--  C57BL/6  55  ±  4  (12):~ 
Anti-IJ  k + C  C57BL/6  5  :tz  5  (11) 
Anti-IJ  b + C  C57BL/6  4  ±  5  (8) 
* Before activation of regional lymph node cells from NP-O-Su-primed mice, the lymph node cells were 
treated with anti I-J antisera and C, as described  in Materials and Methods.  Activation of the lymph 
node cells was done as in Table III. The data represent the pooled results from three separate experiments. 
The data were normalized and the percent suppression ± SE was calculated. 
:~ Significant suppression, P <  0.001. 
the  potential  role  of the  recipient  strains  in  directing  the  genetic  restrictions,  H-2 
heterozygous  Fa recipients were given in vitro activated Ts3 cells. In the first experi- 
ment,  C57BL/6  (H-2  b)  or  B10.BR  (H-2  k)  NP-O-Su-primed  lymph  node  cells were 
used as the source of the Ts3 population. The Ts3 cells were activated for 2 h  in vitro 
with monoclonal B6-Ts2.28 (H-2  b origin) or CKB-Tsz-59 (H-2  k origin) TsF2 and then 
adoptively  transferred  to  (B10  ×  B10.BR)F1  (H-2  b  ×  H-2  k)  NP-O-Su-primed  CY- 
treated  recipients.  As  shown  in  Table  VII,  significant suppression  was  only noted 
when the TsF2 and Ts3 cells were derived from strains that shared H-2 haplotypes. It 
should be noted that after a  2-h activation, CKB (H-2k)-derived TsF~ failed to activate 
C57BL/6  (H-2  b) Ts3 cells, even when the potential suppressive activity of these cells 
was  assayed  in H-2  b  X  H-2  k recipients. These  data  again indicate that  under these 
experimental  conditions a  definite  requirement  for  H-2  homolgy  exists  among  the 
TsF2, Ts3 cells and the recipient strain. 
In  a  second  experiment,  the  role  of  genes  linked  to  the  Igh  complex  was  also 
evaluated. Thus, C57BL/6  (H-2  b, Ighb), CKB  (H-2  k, Ighb), and C3H  (H-2  k, Igh  j) Ts3 
cells were activated for 2 h  with either C57BL/6- or CKB-derived TsF2. The activated 
cells were then adoptively transferred to (C57BL/6 ×  CBA)F1 (H-2b/H-2k; Ighb/Igh  j) 
recipients during the effector  phase of the CS  response.  Only in those combinations 474  ACTIVATION AND INTERACTION OF Tss SUPPRESSOR  CELLS 
TABLE VII 
Suppression ofF1 Recipients by Activated Parental Tsa Cells* 
TsF~ source  Tss donor  CY-treated recipients  Footpad swell- 
ing ± SE 
BW5147  C57BL/6  (B10 X B10.BR)F~  48.5 ± 2.4 
B6-Ts2-28  C57BL/6  (B10 × B10.BR)F~  30.5 ±  1.95 
CKB-Ts2-59  C57BL/6  (B10 × B10.BR)F~  47.3 ± 2.8 
BW5147  B10.BR  (BI0 × B10.BR)F1  50.0 ±  1.9 
B6-Ts2-28  B10.BR  (B10 × B10.BR)F1  47.7 ± 2.2 
CKB-Ts2-59  BI0.BR  (B10 X B10.BR)Fa  35.4 ± 2.95 
BW5147  C57BL/6  (B6 × CBA)Fa  56.6 ± 2.3 
B6-Ts2-28  C57BL/6  (B6 × CBA)F1  31.3 ± 2.3:[: 
CKB-Ts2-59  C57BL/6  (B6 × CBA)F1  54.0 ± 3.5 
BW5147  CKB  (B6 × CBA)FI  56.8 ± 2.7 
B6-Ts2-28  CKB  (B6 × CBA)F~  56.0 ± 2.8 
CKB-Ts2-59  CKB  (B6 x CBA)F1  35.5 ± 2.25 
BW5147  C3H  (B6 x  CBA)F1  58.0 ± 2.2 
B6-Ts2-28  C3H  (B6 x CBA)F~  56.8 ± 2.2 
CKB-Tsa-59  C3H  (B6 × CBA)F~  59.5 ± 2.5 
* Refer to legend for Table III for protocol. The data were expressed as the 
increment  of footpad swelling +  SE in units of 10  -s cm. The background 
response of nonimmunized  (B 10 × B 10.BR)F1 mice was 12.0 +  1.2 and that 
of(B6 × CBA)F1 mice was 10.0 +  1.1. 
:[: Significant suppression, P < 0.01. 
in which the donor of the TsF2, the Tsa, and the recipients shared genes in both the 
H-2 and Igh complexes were significant levels of suppression noted (Table VII). 
Discussion 
The past several years have witnessed numerous advances in our knowledge of the 
mechanisms  of  immunoregulation.  In  some  systems,  three  distinct  T  lymphocyte 
subpopulations  act  in  a  defined sequence  to  mediate  immune  suppression  (20,  21). 
For example, suppression of both cellular (5)  and humoral  (7)  immune responses to 
the NP require a  similar cellular cascade involving Tsl, Ts2, and Tss cells as well as 
factors  derived from  each  of these cell types.  Previous  reports  (5,  13,  16)  from  our 
laboratory characterized a  series of hybridoma T  cell lines representing each of these 
functional  populations.  Furthermore,  we  compared  the  suppressor  factors  (TsF) 
released by each of these Ts cells. The TsF2 and  TsFa factors, which  both  function 
during the effector phase of the immune  response, have similar genetic restrictions. 
Thus,  TsF2  and  TsFs  only suppress  strains  of mice  that  are  homologous  with  the 
factor-producing strain at both the H-2 complex (I-J subregion) and the Igh complex 
(5,  13).  Because  the  basis  for  these  dual  restrictions had  not  been  clarified, it  was 
postulated  that  at  least  some  of  the  restrictions  might  represent  "pseudogenetic 
restrictions," as were initially described for TsF1 factors and cells (16, 22, 23). These 
pseudogenetic  restrictions  reflect  requirements  for  homology  between  H-2  or  Igh 
determinants  that  are present  at  different ends  of the suppressor cell cascade  (16). 
The hypothesis that the dual genetic restrictions of TsFz reflected a  psuedo-restriction 
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from mice of different H-2 haplotypes (13).  The present  protocol was  designed  to 
determine whether the allogeneic cells that could absorb TsF2 could become activated. 
Thus, we developed an experimental system in which the genetics of activation of Ts8 
cells by TsF2 could be analyzed in vitro, independent of the ability of activated Ts3 
cells to interact with their targets. The transfer of Ts3 cells was performed during the 
effector phase,  i.e., along with  the  NP-O-Su  challenge and  within  24-26  h  of the 
termination of the CS response, to minimize potential allogeneic effects. Additional 
controls to exclude potential allogeneic affects included the transfer of nonactivated 
Tss cells that  were cultured with control BW5147-derived factor. Furthermore, F1- 
derived Ts3 cells and F1 recipients were used in combinations in which the direction 
of the allogeneic effect could be controlled (Tables V  and VII). 
The  data  demonstrated  that  NP-specific  Tsa  ceils  are  generated  in  NP-O-Su- 
immune animals concomitant with the CS effector cell population. In contrast to CS 
effector cells, Tsz are very sensitive to low dose CY treatment. The Tsz cells must be 
specifically  activated  by  TsFz  to  manifest  suppression  (Table  I).  Normally,  in  a 
primary NP-O-Su immune response, the Ts3 ceils are not activated. However, later in 
the response the Tsz cells may play an important immunoregulatory role in modulat- 
ing both the cellular and humoral immune response (4, 7). The present data directly 
demonstrate the role of TsF2 in suppressor cell activation. The triggering of Tsa cells 
with TsF2 is rapid. Thus, after 1-2 h of in vitro exposure to TsF2, the activation of Ts3 
cells appears irreversible and results in optimum levels of suppression  (Fig.  1). This 
rapid activation process presumably reflects the fact that the antigen-primed Tsa cells 
have already expanded and  differentiated. These cells apparently await  a  terminal 
signal for activation and/or release of biologically active mediators, such as TsF3. 
The specificity of Ts3 cell-mediated suppression was  demonstrated  in  two ways. 
First,  NP-specific Tsz cells are generated after NP-O-Su priming, whereas immuni- 
zation with  another antigen  (e.g.,  DNFB)  does not  generate NP-reactive Tsz cells. 
Furthermore, once NP-O-Su-induced Ts3 ceils are activated with TsF2, they suppress 
only NP-O-Su-induced CS responses even in animals that have been doubly primed 
or challenged with NP-O-Su plus DNFB (Table II). Although under the experimental 
conditions described in this report immune suppression is antigen specific, nonspecific 
suppression of immune response has been noted in other systems in which different 
experimental conditions are used (10-12). This disparity might reflect the requirement 
for the  suppressor  cell  and  the  potential  targets  to  be  in  very close proximity to 
mediate suppression. 
Genetic analyses of the TsF2-Tsa-target cell interaction indicated the requirement 
for Igh homology was absolute. Thus, CKB (Ighb)-derived TsF2 would only activate 
an  Igh-compatible Tsa population,  which  in turn only suppressed  Igh  homologous 
recipients  (Table III).  These results,  along with  previous data  (24)  demonstrating 
anti-idiotypic receptors on Tsz cells and factors as well as previous data demonstrating 
the presence of Npb-related idiotypic determinants on TSl and Ts3 cells, suggests that 
suppressor T  cell interactions proceed via a series of idiotypic-anti-idiotypic interac- 
tions in accord with Jerne's network hypothesis. In addition to the absolute require- 
ment for Igh homology with respect to the cells involved in suppression of the effector 
phase of the contact sensitivity response, there also is an H-2 restriction that controls 
the interaction of these cells. Thus, after activation, the series of interactions between 
TsF2, Tsa, and  the  recipient strain  appears  to be completely H-2 restricted. These 476  ACTIVATION AND INTERACTION OF Ts3 SUPPRESSOR CELLS 
H-2 restrictions can be more precisely mapped to the I-J subregion of the H-2 complex 
(Table IV), which has also been shown to regulate suppressor cell interactions in other 
systems (17, 25, 26). The physiological meaning of this I-J restriction is unknown. We 
have not yet determined the directionality of the restriction; i.e., do Ts3 cells have a 
receptor for I-J  determinants  on  a  target  population  or are  the  I-J  determinants 
present on Tsa cells and factors recognized by the target population? 
To further evaluate the genetic restrictions on activated Tss cells, (B 10 ×  B 10.BR)F1 
hybrid-derived Tss were cultured with  either H-2  b-  or H-2k-derived TsF2, and  the 
activated Tsa were tested for suppressive activity in either C57BL/6 (H-2  b) or B 10.BR 
(H-2  k) recipients. The data again demonstrate that the critical requirements for H-2 
homology were between the  H-2 type of the TsF2 donor and  the  H-2  type of the 
recipients of activated Ts3 cells.  Thus,  a  C57BL/6-derived TsF2 activated  (B10  X 
B 10.BR)Fl-derived Ts3 cells, as evidenced by their ability to suppress NP-induced CS 
responses in C57BL/6 mice. It should be noted that the same population of activated 
Tss cells failed to suppress NP-O-Su  CS responses in B10.BR recipients  (Table V). 
Reciprocal data  were obtained  when  CKB-derived TsF2  was  used  to  activate  Fa- 
derived Ts3 cells (Table V). The simplest explanation for these observations is that 
two distinct populations of Tsa cells exist in heterozygous Fa donors, each restricted to 
a  parental I-J determinant. This hypothesis is analogous to the findings noted with 
Fl-derived helper T  cells  (18,  19).  By extending this  analogy with  helper T  cells 
further,  one  can  postulate  that  the  induction  of I-J  restrictions  might  reflect  the 
requirement for the initial presentation of antigen in the context of I-J determinants. 
Preliminary experiments support the latter postulate. 
The next series of experiments was aimed at determining whether I-J determinants 
were  allelically excluded  in  the  H-2  heterozygous Ts3  population.  If only one I-J 
determinant  was expressed on each subset  of Fl-derived Ts3 cells, it  could help to 
explain  the  directionality of the  genetic  restriction.  The data  in  Table VI  clearly 
demonstrate that these I-J determinants are not allelically excluded in confirmation 
of the results reported by Okuda et al.  (27), who arrived at similar conclusions in a 
different type of experimental system. However, because both I-J determinants are 
expressed on Ts3 cells of F1 origin, it will be important to analyze TsFs of F1 origin to 
determine whether both I-J determinants are also present on these factors. Separate 
experiments are planned to address these questions. 
Finally, we evaluated the role of the recipient strain in these genetic restrictions. By 
using F1 recipients, we again confirmed the requirements for homology at both H-2 
and Igh complexes. The recipient strain must contain the cells that are the target of 
the activated Tss population. However, the present data do not permit us to determine 
the nature of these target cells. The target cells could be the CS effector cells, a Ts4 
population, or even an antigen-presenting cell. Whatever the nature of the target, we 
expect that  it will either bear I-J determinants or receptors for I-J, and it may also 
bear anti-idiotypic receptors. Furthermore, the data obtained after a  2-h activation 
argue  against  the  notion  that  the  dual  genetic  restrictions  of TsF2  and  TsFa  are 
pseudogenetie restrictions,  as  were  defined  for Tsl-derived  factors  (16,  22,  23).  In 
addition, some experimental data indicate that TsF3 may have a two-chain structure, 
one polypeptide containing I-J  determinants and  the other idiotypic determinants 
(28) (Furusawa, et al., unpublished data). The dual genetic restriction of Tsa cells and 
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portions of the TsFa molecule. The significance of these dual restrictions (I-J and Igh) 
might lie in the fact that  two recognition signals are required  for the activation of 
effector-suppressor cells. Such a  two-signal model could account for the specifcity of 
suppression as well as the molecular structure of the factor. 
Summary 
An experimental system was developed to independently analyze the H-2 and Igh 
genetic  restrictions  at  two  steps  of the 4-hydroxy-3-nitrophenylacetyl hapten  (NP) 
suppressor  cell  pathway.  This  experimental system allowed  genetic  analysis of the 
activation of Ts8 cells by hybridoma-derived TsF2  and independent  analysis of the 
genetic  restrictions  that  controlled  the interaction  of the Ts3 cells with their target 
population.  Thus, Ts~ cells were activated in  vitro with  monoclonal  H-2  b or H-2  k- 
derived TsF2. The activated Tsa cells were then adoptively transferred to Ts3-depleted 
(cyclophosphamide-treated) recipients of various genotypes. When the Tsa-containing 
lymph node population was activated in vitro for 2 h, suppressive activity was only 
noted in combinations of TsF2, Tss, and recipients that were matched at both the I-J 
and Igh gene complexes. The data indicate that TsF2 can activate Tsa cells and that 
both the activation and the interaction of Tss cells are I-J and Igh restricted.  Using 
(B10  X  B10.BR)F1  mice as Tsa donors,  we noted  that  H-2b-derived TsF2 activated 
these Fz Tsa cells to suppress NP-specific cutaneous sensitivity responses in H-2  b but 
not in H-2  k recipients. Reciprocal experiments using H-2k-derived TsF2 demonstrated 
that only an H-2k-restricted population was activated in the Frderived Tsa cells. The 
simplest explanation to account for these observations is that two distinct populations, 
each of which is restricted to a  parental I-J determinants, exists in the heterozygous 
Fz Tss population. Furthermore, we demonstrated that both I-J  b and I-J  k determinants 
are expressed on Frderived Tsa cells. These observations are discussed in terms of the 
mechanisms involved in immunoregulation. 
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